To do so, they performed a retrospective review of their institutional database of patients who underwent MWA for RCC from 2013 to 2017. They abstracted data on demographics, tumor characteristics, procedural protocol, and follow-up visits within the 6-month postoperative period.
Their final analytical cohort included 70 patients with 88 biopsy-proven RCC tumors. The median (range) nephrometry score was 8 (4 - 11) and the median (range) size was 2.5 cm (0.8 – 7.4). There was no significant change in the estimated glomerular filtration rate pre- and post-ablation. The overall technical success rate was 100%. The overall complications rate was 6.8%; complications included hematoma and pain. The recurrence rate was 6.9% and occurred predominantly in those patients with clear cell RCC.
The authors concluded that ultrasound- and contrast computed tomography-guided MWA is a safe and effective treatment option with low recurrence and complication rates in those patients with T1a and T1b RCCs.
Future directions include assessing this patient cohort at a longer length of follow-up.
Presented by: Sepideh Shakeri
Written by: Michael Owyong, Department of Urology, University of California-Irvine at the 2018 AUA Annual Meeting - May 18 - 21, 2018 – San Francisco, CA USA